Citadel Advisors
HUMA icon

Citadel Advisors’s Humacyte HUMA Stock Holding History

Citadel Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Buy
232,100
+98,200
+73% +$102K ﹤0.01% 11737
2025
Q4 		$129K Buy
133,900
+60,600
+83% +$85.8K ﹤0.01% 11447
2025
Q3 		$128K Sell
73,300
-25,500
-26% -$50K ﹤0.01% 11656
2025
Q2 		$206K Sell
98,800
-44,000
-31% -$84.5K ﹤0.01% 10621
2025
Q1 		$243K Sell
142,800
-151,400
-51% -$568K ﹤0.01% 10050
2024
Q4 		$1.49M Sell
294,200
-10,600
-3% -$52.4K ﹤0.01% 6253
2024
Q3 		$1.66M Sell
304,800
-126,800
-29% -$836K ﹤0.01% 5873
2024
Q2 		$2.07M Buy
431,600
+337,200
+357% +$1.75M ﹤0.01% 5231
2024
Q1 		$294K Buy
94,400
+43,900
+87% +$148K ﹤0.01% 9485
2023
Q4 		$143K Sell
50,500
-12,500
-20% -$32.1K ﹤0.01% 10450
2023
Q3 		$185K Buy
63,000
+26,300
+72% +$87K ﹤0.01% 10047
2023
Q2 		$105K Buy
+36,700
New +$132K ﹤0.01% 10863
2023
Q1 		– Sell
-14,900
Closed -$31.4K – 15041
2022
Q4 		$31.4K Buy
+14,900
New +$45.2K ﹤0.01% 12684
2022
Q2 		– Sell
-19,100
Closed -$135K – 13389
2022
Q1 		$135K Sell
19,100
-17,300
-48% -$101K ﹤0.01% 11969
2021
Q4 		$264K Sell
36,400
-40,200
-52% -$398K ﹤0.01% 11215
2021
Q3 		$889K Buy
+76,600
New +$876K ﹤0.01% 8448

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's HUMA Position: Q1 2026 in Review

Citadel Advisors sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 1,566,431 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in HUMA in Q4 2021 and held it in 16 quarters. The position peaked at $4.96M in Q1 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Citadel Advisors reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,566,431 Humacyte shares in Q1 2026, an estimated $1.63M.
  • Citadel Advisors first reported a position in Humacyte in Q4 2021 and held it in 16 quarters.
  • Citadel Advisors's Humacyte position peaked at $4.96M in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.